CliffBio
small molecule

FLEQSUVY

BACLOFEN

Loss of exclusivitySeptember 2037latest FDA-listed patent expiry
CompanyAzurity Pharmaceuticals →View the full company profile on CliffBio

Drug detail

Brand nameFLEQSUVY
Active ingredientBACLOFEN
Strength25MG/5ML
Dosage formSUSPENSION
RouteORAL
ModalitySmall molecule
FDA approvalFebruary 2022
Marketing statusRX

Listed patents

PatentExpiresType
11324696September 2037product
11446246September 2037use U-3433

More from Azurity Pharmaceuticals

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

FLEQSUVY patent cliff — loss of exclusivity September 2037 | CliffBio